Patient characteristics
| Variable . | Total (n = 157) . | MSD (n = 68) . | UCB (n = 89) . | P . |
|---|---|---|---|---|
| Age, y | ||||
| Median (range) | 61 (21-73) | 60 (21-73) | 61 (22-73) | .35 |
| <60 | 74 (47) | 35 (52) | 39 (44) | .34 |
| ≥60 | 83 (53) | 33 (49) | 50 (56) | — |
| Sex | .64 | |||
| Male | 91 (58) | 38 (56) | 53 (60) | |
| Female | 66 (42) | 30 (44) | 36 (40) | |
| HCT-CI | .58 | |||
| 0 | 49 (31) | 24 (35) | 25 (28) | |
| 1-2 | 59 (38) | 23 (34) | 36 (40) | |
| ≥3 | 48 (31) | 21 (31) | 27 (30) | |
| Missing | 1 (1) | — | 1 (1) | |
| Disease risk index | .27 | |||
| Low | 24 (15) | 14 (21) | 10 (11) | |
| Intermediate | 110 (70) | 45 (66) | 65 (73) | |
| High/very high | 23 (15) | 9 (13) | 14 (16) | |
| Diagnosis | .77 | |||
| Leukemia | 103 (66) | 43 (63) | 60 (67) | |
| Lymphoma | 39 (25) | 19 (28) | 20 (23) | |
| Other | 4 (3) | 1 (2) | 3 (3) | |
| ATG in conditioning | .82 | |||
| Yes | 43 (27) | 18 (27) | 25 (28) | |
| No | 114 (73) | 50 (74) | 64 (72) | |
| CMV seropositive | .92 | |||
| Yes | 87 (55) | 38 (56) | 49 (55) | |
| No | 70 (45) | 30 (44) | 40 (45) | |
| Total infused cell count, median (range) | — | |||
| TNC, ×108/kg | — | 7.8 (4.3-31.6) | 0.4 (0.2-0.9) | |
| CD3, ×108/kg | — | 2.7 (1.2-6.9) | 0.2 (0.1-0.8) | |
| CD34, ×106/kg | — | 5.5 (2.0-18.2) | 0.5 (0.2-3.5) | |
| Follow-up time for survivors, median (range), mo | 35 (12-65) | 35 (12-61) | 35 (12-65) | .51 |
| Variable . | Total (n = 157) . | MSD (n = 68) . | UCB (n = 89) . | P . |
|---|---|---|---|---|
| Age, y | ||||
| Median (range) | 61 (21-73) | 60 (21-73) | 61 (22-73) | .35 |
| <60 | 74 (47) | 35 (52) | 39 (44) | .34 |
| ≥60 | 83 (53) | 33 (49) | 50 (56) | — |
| Sex | .64 | |||
| Male | 91 (58) | 38 (56) | 53 (60) | |
| Female | 66 (42) | 30 (44) | 36 (40) | |
| HCT-CI | .58 | |||
| 0 | 49 (31) | 24 (35) | 25 (28) | |
| 1-2 | 59 (38) | 23 (34) | 36 (40) | |
| ≥3 | 48 (31) | 21 (31) | 27 (30) | |
| Missing | 1 (1) | — | 1 (1) | |
| Disease risk index | .27 | |||
| Low | 24 (15) | 14 (21) | 10 (11) | |
| Intermediate | 110 (70) | 45 (66) | 65 (73) | |
| High/very high | 23 (15) | 9 (13) | 14 (16) | |
| Diagnosis | .77 | |||
| Leukemia | 103 (66) | 43 (63) | 60 (67) | |
| Lymphoma | 39 (25) | 19 (28) | 20 (23) | |
| Other | 4 (3) | 1 (2) | 3 (3) | |
| ATG in conditioning | .82 | |||
| Yes | 43 (27) | 18 (27) | 25 (28) | |
| No | 114 (73) | 50 (74) | 64 (72) | |
| CMV seropositive | .92 | |||
| Yes | 87 (55) | 38 (56) | 49 (55) | |
| No | 70 (45) | 30 (44) | 40 (45) | |
| Total infused cell count, median (range) | — | |||
| TNC, ×108/kg | — | 7.8 (4.3-31.6) | 0.4 (0.2-0.9) | |
| CD3, ×108/kg | — | 2.7 (1.2-6.9) | 0.2 (0.1-0.8) | |
| CD34, ×106/kg | — | 5.5 (2.0-18.2) | 0.5 (0.2-3.5) | |
| Follow-up time for survivors, median (range), mo | 35 (12-65) | 35 (12-61) | 35 (12-65) | .51 |
Values are reported as n (%) of patients, unless indicated otherwise.
HCT-CI, hematopoietic cell transplant comorbidity index; TNC, total nucleated cell.